Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Price:
17.29
CNY
0.35%
Market Cap:
¥41.4B
Relative Value
The Relative Value of one
Chongqing Zhifei Biological Products Co Ltd
stock under the Base Case scenario is
13.97
CNY.
Compared to the current market price of 17.29 CNY,
Chongqing Zhifei Biological Products Co Ltd
is
Overvalued by 19%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
13.97
CNY
Overvaluation 19%
Multiples Across Competitors
Competitors Multiples
Chongqing Zhifei Biological Products Co Ltd Competitors
Chongqing Zhifei Biological Products Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
41.4B CNY | 3.8 | -30.9 | -36.4 | -36.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
407.7B USD | 6.7 | 97.4 | 16 | 22.2 | |
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD | 462 374.5 | -2 631.9 | -2 389.6 | -2 389.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
208.4B USD | 5.7 | 27 | 15.4 | 15.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
185.3B USD | 6.3 | 21.8 | 13.5 | 16.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
125.9B USD | 10.5 | 31.9 | 24.1 | 25.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD | 5.7 | 18.3 | 13.7 | 15.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70.9B AUD | 3.3 | 36 | 11.8 | 14.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.9B EUR | 11.4 | 36.5 | 39.7 | 40.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
